Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Generic Exclusivity Awards Process Might Go Public

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA wants to know whether 180-day exclusivity should be revealed up front; question is one of many on ANDA reviews to be considered at September public hearing.

You may also be interested in...



Generic Exclusivity? Who Cares! Industry Offers Few Opinions On Potential Changes

U.S. FDA officials still looking for input after transparency issue not widely addressed during GDUFA policy meeting.

Generic Exclusivity? Who Cares! Industry Offers Few Opinions On Potential Changes

FDA officials still looking for input after transparency issue not widely addressed during GDUFA policy meeting.

ANDA Communication Complaints: FDA Takes Licking, Keeps Ticking

As sponsors vent about uncertain status of their ANDAs, FDA Office of Generic Drugs indicates number of ideas are in process, including providing target action dates for applications without formal review goals.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS077563

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel